CN100428936C - 抗病毒化合物 - Google Patents

抗病毒化合物 Download PDF

Info

Publication number
CN100428936C
CN100428936C CNB028099044A CN02809904A CN100428936C CN 100428936 C CN100428936 C CN 100428936C CN B028099044 A CNB028099044 A CN B028099044A CN 02809904 A CN02809904 A CN 02809904A CN 100428936 C CN100428936 C CN 100428936C
Authority
CN
China
Prior art keywords
ester
virus
purposes
octahydro
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028099044A
Other languages
English (en)
Chinese (zh)
Other versions
CN1516582A (zh
Inventor
A·S·蒂姆斯
D·L·泰勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Sanofi Aventis France
Original Assignee
Virogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogen Ltd filed Critical Virogen Ltd
Publication of CN1516582A publication Critical patent/CN1516582A/zh
Application granted granted Critical
Publication of CN100428936C publication Critical patent/CN100428936C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB028099044A 2001-05-03 2002-05-02 抗病毒化合物 Expired - Lifetime CN100428936C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0110832.3A GB0110832D0 (en) 2001-05-03 2001-05-03 Antiviral compounds
GB0110832.3 2001-05-03

Publications (2)

Publication Number Publication Date
CN1516582A CN1516582A (zh) 2004-07-28
CN100428936C true CN100428936C (zh) 2008-10-29

Family

ID=9913938

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028099044A Expired - Lifetime CN100428936C (zh) 2001-05-03 2002-05-02 抗病毒化合物

Country Status (19)

Country Link
US (1) US7601735B2 (https=)
EP (1) EP1387681B1 (https=)
JP (2) JP2004527566A (https=)
KR (1) KR100660241B1 (https=)
CN (1) CN100428936C (https=)
AT (1) ATE405261T1 (https=)
AU (1) AU2002341155B2 (https=)
CA (1) CA2445271A1 (https=)
CY (1) CY1110437T1 (https=)
DE (1) DE60228436D1 (https=)
DK (1) DK1387681T3 (https=)
ES (1) ES2312587T3 (https=)
GB (1) GB0110832D0 (https=)
IL (2) IL158558A0 (https=)
NO (1) NO326292B1 (https=)
NZ (1) NZ529448A (https=)
PT (1) PT1387681E (https=)
WO (1) WO2002089780A2 (https=)
ZA (1) ZA200308483B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0116643D0 (en) * 2001-07-09 2001-08-29 Virogen Ltd Antiviral compounds
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
WO2006085141A2 (en) * 2004-08-13 2006-08-17 Migenix Inc. Compositions and methods for treating or preventing hepadnaviridae infection
MX2007003853A (es) * 2004-10-06 2007-11-21 Migenix Inc Composiciones antivirales en combinacion que comprenden castanospermina y metodos de uso.
JP2008530124A (ja) * 2005-02-09 2008-08-07 ミジェニックス インコーポレイテッド フラビウイルス感染症を処置または予防するための組成物および方法
JP2007297289A (ja) * 2006-04-27 2007-11-15 Kitasato Gakuen 抗ウイルス剤
US20080131398A1 (en) * 2006-08-21 2008-06-05 United Therapeutics Corporation Combination therapy for treatment of viral infections
KR101314166B1 (ko) * 2011-06-16 2013-10-04 건국대학교 산학협력단 석이버섯 가수분해 효소 추출물 또는 이로로부터 분리된 화합물을 유효성분으로 함유하는 항산화 조성물
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
CN102343083A (zh) * 2011-10-17 2012-02-08 中国科学院成都生物研究所 一种抗病毒的组合药物
MY170991A (en) 2013-03-15 2019-09-23 60? Pharmaceuticals Llc Dosing regimens of celgosivir for the treatment of dengue
MD4794B1 (ro) 2013-09-27 2022-02-28 Merck Sharp & Dohme Corp Derivaţi de chinolizină substituiţi utili ca inhibitori de integrază HIV
US10046005B2 (en) * 2014-02-07 2018-08-14 Shaker A. Mousa Composition and method of use for combinations of anti-viral protease, polymerase inhibitors and natural bioactive compounds in the treatment of hepatitis C infection
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SG10201912141YA (en) * 2015-12-11 2020-02-27 60 Pharmaceuticals Llc Novel dosing regimens of celgosivir for the prevention of dengue
MX2018011788A (es) 2016-03-31 2019-05-20 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
KR102359766B1 (ko) 2016-04-01 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서 치환된 인돌 화합물 유도체
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201992782A1 (ru) 2017-05-22 2020-03-24 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
CN110753682B (zh) 2017-05-22 2023-06-30 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
JP7497790B2 (ja) * 2019-12-27 2024-06-11 国立大学法人北海道大学 豚コレラの治療及び／又は予防剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029321A1 (en) * 1997-12-11 1999-06-17 The Chancellor, Masters And Scholars Of The University Of Oxford Inhibition of membrane-associated viral replication
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1315276C (en) 1987-07-02 1993-03-30 Paul S. Liu Castanospermine esters and glycosides
US5004746A (en) 1987-09-29 1991-04-02 Merrell Dow Pharmaceuticals Inc. Anti-retroviral castanospermine esters
US4849430A (en) 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
US5017563A (en) * 1988-06-23 1991-05-21 Merrell Dow Pharmaceuticals Inc. Castanospermine esters and glycosides
US4970317A (en) 1989-08-08 1990-11-13 Merrell Dow Pharmaceuticals Inc. Process for the preparation of castanospermine esters
US5093501A (en) 1990-03-12 1992-03-03 Merrell Dow Pharmaceuticals Inc. Intermediates in a process for the preparation of castanospermine
US5066807A (en) 1990-03-12 1991-11-19 Merrell Dow Pharmaceuticals Inc. Process for the preparation of castanospermine
GB9027433D0 (en) 1990-12-18 1991-02-06 Merrell Dow Pharma Anti-herpes castanospermine esters
GB9719189D0 (en) * 1997-09-09 1997-11-12 Glaxo Group Ltd New therapeutic method
US5959111A (en) 1997-05-22 1999-09-28 Hoechst Marion Roussel, Inc. Process for preparing 6-0-monoesters of castanospermine
AU2001234596A1 (en) * 2000-01-28 2001-08-07 Timothy M Block Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
WO1999029321A1 (en) * 1997-12-11 1999-06-17 The Chancellor, Masters And Scholars Of The University Of Oxford Inhibition of membrane-associated viral replication

Also Published As

Publication number Publication date
JP2004527566A (ja) 2004-09-09
IL158558A (en) 2011-09-27
HK1068538A1 (zh) 2005-04-29
EP1387681A2 (en) 2004-02-11
IL158558A0 (en) 2004-05-12
US7601735B2 (en) 2009-10-13
WO2002089780A2 (en) 2002-11-14
NO20034878L (no) 2003-12-22
CA2445271A1 (en) 2002-11-14
DE60228436D1 (de) 2008-10-02
JP2005290015A (ja) 2005-10-20
CN1516582A (zh) 2004-07-28
KR100660241B1 (ko) 2006-12-20
ES2312587T3 (es) 2009-03-01
DK1387681T3 (da) 2009-01-05
ZA200308483B (en) 2005-10-26
CY1110437T1 (el) 2015-04-29
US20040147549A1 (en) 2004-07-29
PT1387681E (pt) 2008-12-02
ATE405261T1 (de) 2008-09-15
NZ529448A (en) 2005-11-25
WO2002089780A3 (en) 2003-03-06
NO20034878D0 (no) 2003-10-31
GB0110832D0 (en) 2001-06-27
JP4406383B2 (ja) 2010-01-27
AU2002341155B2 (en) 2007-10-18
EP1387681B1 (en) 2008-08-20
NO326292B1 (no) 2008-11-03
KR20040007527A (ko) 2004-01-24

Similar Documents

Publication Publication Date Title
CN100428936C (zh) 抗病毒化合物
CN101448497B (zh) 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用
TW200412960A (en) Potent inhibitor of HCV serine protease
BG63612B1 (bg) Състав и метод за профилактика и лечение на нiv идруги инфекциозни заболявания при човека
JP2014141506A (ja) デングウイルス感染を治療及び予防するためのチエノピリジン誘導体類
AU2002341155A1 (en) Antiviral compounds
CA2481092A1 (en) Low dose liquid entecavir formulations and use
EP4151216B1 (en) Compound for treating and/or preventing diseases caused by coronavirus and use thereof
JPH07507770A (ja) Ｎ−（ホスホノアセチル）−ｌ−アスパラギン酸組成物，および広域抗ウイルス剤としてのその使用方法
PL190505B1 (pl) Kompozycja farmaceutyczna i sposób jej wytwarzania
CN107998400B (zh) 一种药物组合物及其在制备治疗黄病毒属病毒感染的药物中的应用
Jabeen et al. A review on the antiparasitic drug ivermectin for various viral infections and possibilities of using it for novel severe acute respiratory syndrome coronavirus 2: New hope to treat coronavirus disease-2019
CN118772098B (zh) 一类具有抗炎保肝活性呋喃类化合物、其制备及用途
HK1068538B (en) Antiviral compounds
CN119587555B (zh) 依碳氯替泼诺作为nlrp3炎症小体激活抑制剂的用途
CN111067898B (zh) 盐酸小檗碱在水产养殖中抗鲤疱疹病毒ⅱ型的用途
JPWO1997030706A1 (ja) 抗腫瘍剤含有組成物
CN120757568A (zh) 一类具有抗炎保肝活性磺酰基取代氮丙啶类化合物、其制备及用途
CN118178362A (zh) 2,2'-（2-亚甲基丙烷-1,3-二基）双（4-异丙基苯酚）在制备nlrp3炎性小体抑制剂中的应用
KR100293299B1 (ko) 레트로비루스억제제배합물
CN120960185A (zh) 麝香酮在制备病毒抑制剂中的应用
KR101475056B1 (ko) 설폰아미드계 화합물을 유효성분으로 포함하는 ｃ형 간염의 예방 또는 치료용 약학적 조성물
CN119454587A (zh) 一种包含茄尼醇的药物组合物及其制备方法和用途
CN121003699A (zh) 抑制黄病毒属病毒感染的药物及应用
CN121818710A (zh) 绿藻基碳量子点在制备抗基孔肯雅病毒感染药物或洗消剂中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1068538

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1068538

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: SANOFI SYNTHELABO

Free format text: FORMER OWNER: VIROGEN LTD.

Effective date: 20120912

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: SANOFI

Free format text: FORMER NAME: SANOFI SYNTHELABO

CP01 Change in the name or title of a patent holder

Address after: Paris France

Patentee after: Sanofi

Address before: Paris France

Patentee before: SANOFI-AVENTIS

TR01 Transfer of patent right

Effective date of registration: 20120912

Address after: Paris France

Patentee after: SANOFI-AVENTIS

Address before: London, England

Patentee before: Virogen Ltd.

CX01 Expiry of patent term

Granted publication date: 20081029

CX01 Expiry of patent term